Entera Bio Statistics

Total Valuation

Entera Bio has a market cap or net worth of $77.35 million. The enterprise value is $70.74 million.

Market Cap	77.35M
Enterprise Value	70.74M

Important Dates

The last earnings date was Friday, November 8, 2024, after market close.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	n/a

Share Statistics

Entera Bio has 36.83 million shares outstanding. The number of shares has increased by 22.42% in one year.

Current Share Class	36.83M
Shares Outstanding	36.83M
Shares Change (YoY)	+22.42%
Shares Change (QoQ)	+1.49%
Owned by Insiders (%)	2.22%
Owned by Institutions (%)	3.91%
Float	24.35M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	11.88
P/TBV Ratio	11.99
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	714.56
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 6.61, with a Debt / Equity ratio of 0.05.

Current Ratio	6.61
Quick Ratio	6.26
Debt / Equity	0.05
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -144.67% and return on invested capital (ROIC) is -85.93%.

Return on Equity (ROE)	-144.67%
Return on Assets (ROA)	-70.61%
Return on Capital (ROIC)	-85.93%
Revenue Per Employee	$5,500
Profits Per Employee	-$509,889
Employee Count	18
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +195.82% in the last 52 weeks. The beta is 1.56, so Entera Bio's price volatility has been higher than the market average.

Beta (5Y)	1.56
52-Week Price Change	+195.82%
50-Day Moving Average	1.84
200-Day Moving Average	1.90
Relative Strength Index (RSI)	58.28
Average Volume (20 Days)	54,806

Short Selling Information

Short Interest	62,957
Short Previous Month	52,613
Short % of Shares Out	0.17%
Short % of Float	0.26%
Short Ratio (days to cover)	0.54

Income Statement

In the last 12 months, Entera Bio had revenue of $99,000 and -$9.18 million in losses. Loss per share was -$0.26.

Revenue	99,000
Gross Profit	9,000
Operating Income	-9.21M
Pretax Income	-8.51M
Net Income	-9.18M
EBITDA	-9.16M
EBIT	-9.21M
Loss Per Share	-$0.26

Full Income Statement

Balance Sheet

The company has $6.92 million in cash and $309,000 in debt, giving a net cash position of $6.61 million or $0.18 per share.

Cash & Cash Equivalents	6.92M
Total Debt	309,000
Net Cash	6.61M
Net Cash Per Share	$0.18
Equity (Book Value)	6.45M
Book Value Per Share	0.18
Working Capital	6.23M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$7.97 million and capital expenditures -$5,000, giving a free cash flow of -$7.97 million.

Operating Cash Flow	-7.97M
Capital Expenditures	-5,000
Free Cash Flow	-7.97M
FCF Per Share	-$0.22

Full Cash Flow Statement

Margins

Gross Margin	9.09%
Operating Margin	-9,304.04%
Pretax Margin	-9,270.71%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Entera Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-22.42%
Shareholder Yield	-22.42%
Earnings Yield	-11.87%
FCF Yield	-10.31%

Analyst Forecast

The average price target for Entera Bio is $10.00, which is 376.19% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$10.00
Price Target Difference	376.19%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Entera Bio has an Altman Z-Score of 0.12 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.12
Piotroski F-Score	3